The emphysema market is in trends by advancements in personalized treatment approaches. Emphysema is a type of chronic obstructive pulmonary disease (COPD) characterized by damage to the air sacs (alveoli) in the lungs. This damage leads to the air sacs becoming overinflated with air, reducing their elasticity and making it more difficult to breathe. Therapies for emphysema aim to target lung damage and improve symptoms through anti-inflammatory drugs, oxygen therapy, bronchodilators, and lung volume reduction procedures.
The global emphysema market is estimated to be valued at US$ 7.2 Billion in 2028 and is expected to exhibit a CAGR of 3.8% over the forecast period 2028-2033.
Key Takeaways
Key players operating in the emphysema market are GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., AstraZeneca, Boehringer Ingelheim GmbH, and Novartis AG. Advancements in targeted drug delivery through inhalers and development of combination therapies have strengthened the product offerings of these market leaders.
Growing demand for non-invasive and personalized treatment regimens is fueling market growth. Minimally invasive lung volume reduction techniques like emphysema lung sealing using external pulmonary sealing (ExPSe) offer safe and effective lung volume reduction without surgery. Such techniques help reduce lung volume, restore elastic recoil, and improve lung compliance, thereby reducing symptoms.
Increasing global disease prevalence along with rising healthcare expenditure in developing regions is further propelling the emphysema market globally. According to WHO reports, over 384 million people suffer from COPD worldwide with emphysema being a major type. Market players are eyeing emerging Asian and Latin American countries for lucra Expanding access to state-of-the-art therapies in these regions presents significant opportunities.
Market Key Trends
One of the key trends in the emphysema market is the focus on precision and personalized medicine approaches. Companies are developing diagnostic tools and biomarkers to better phenotype and subclassify patients based on their molecular and clinical profile. This enables matching patients to tailored treatment regimens best suited to slow disease progression. For instance, Genentech’s ECLIPSE trial evaluates the efficacy of tezepelumab in various phenotypes of severe asthma defined by biomarkers. Such initiatives aim to move beyond one-size-fits-all treatment strategies.
Porter’s Analysis
Threat of new entrants: The emphysema market has moderate threat of new entrants due to high capital requirement for R&D and manufacturing. However, opportunities exist for new therapies.
Bargaining power of buyers: Individual buyers have low bargaining power compared to hospitals and other healthcare providers who purchase in bulk. Buyers prefer therapies with proven efficacy and safety.
Bargaining power of suppliers: A few large players like GlaxoSmithKline and Boehringer Ingelheim control the supply of drugs used for emphysema treatment, giving them significant pricing power.
Threat of new substitutes: Ongoing research on new therapies could lead to substitutes, but developing novel treatments requires extensive clinical testing before gaining approvals.
Competitive rivalry: The market is dominated by a few major companies with established portfolios. Competition is based on product differentiation, clinical evidence and investment in R&D.
North America accounts for the largest regional market for emphysema treatment, owing to high disease prevalence, healthcare investments and adoption of advanced therapies. The region held over 40% value share in 2020.
The Asia Pacific region is seeing rapid growth in the emphysema market due to growing disease awareness, expanding healthcare infrastructure and increasing healthcare expenditures across developing countries. Countries like China and India are projected to increase their market share significantly in the coming years.
What Are The Key Data Covered In This Emphysema Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Emphysema’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Emphysema and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Emphysema Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Emphysema vendors
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.